No Data
Express News | Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings Trajectory Could Turn Positive as the Stock Climbs 5.5% This Past Week
As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. We regret
How Is The Market Feeling About Jazz Pharmaceuticals?
Jazz Pharmaceuticals's (NYSE:JAZZ) short percent of float has risen 4.88% since its last report. The company recently reported that it has 2.68 million shares sold short, which is 5.59% of all
Morgan Stanley Maintains Jazz Pharmaceuticals(JAZZ.US) With Hold Rating, Cuts Target Price to $150
Morgan Stanley analyst Jeffrey Hung maintains $Jazz Pharmaceuticals(JAZZ.US)$ with a hold rating, and adjusts the target price from $160 to $150.According to TipRanks data, the analyst has a success
Jazz Pharmaceuticals (JAZZ) Receives a Hold From Morgan Stanley
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long